- Home
- VTGN vs ONCY Comparison
VTGN vs ONCY Comparison
Compare VTGN & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTGN
- ONCY
- Stock Information
- Founded
- VTGN 1998
- ONCY 1998
- Country
- VTGN United States
- ONCY Canada
- Employees
- VTGN N/A
- ONCY N/A
- Industry
- VTGN Biotechnology: Pharmaceutical Preparations
- ONCY Pharmaceuticals and Biotechnology
- Sector
- VTGN Health Care
- ONCY Health Care
- Exchange
- VTGN Nasdaq
- ONCY Nasdaq
- Market Cap
- VTGN 87.2M
- ONCY 89.7M
- IPO Year
- VTGN N/A
- ONCY 1999
- Fundamental
- Price
- VTGN $3.94
- ONCY $1.38
- Analyst Decision
- VTGN
- ONCY Strong Buy
- Analyst Count
- VTGN 0
- ONCY 5
- Target Price
- VTGN N/A
- ONCY $5.00
- AVG Volume (30 Days)
- VTGN 557.1K
- ONCY 1.2M
- Earning Date
- VTGN 11-06-2025
- ONCY 11-11-2025
- Dividend Yield
- VTGN N/A
- ONCY N/A
- EPS Growth
- VTGN N/A
- ONCY N/A
- EPS
- VTGN N/A
- ONCY N/A
- Revenue
- VTGN $646,000.00
- ONCY N/A
- Revenue This Year
- VTGN $10.19
- ONCY N/A
- Revenue Next Year
- VTGN $705.79
- ONCY N/A
- P/E Ratio
- VTGN N/A
- ONCY N/A
- Revenue Growth
- VTGN N/A
- ONCY N/A
- 52 Week Low
- VTGN $1.90
- ONCY $0.33
- 52 Week High
- VTGN $4.00
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- VTGN 70.88
- ONCY 60.09
- Support Level
- VTGN $3.44
- ONCY $1.20
- Resistance Level
- VTGN $3.75
- ONCY $1.47
- Average True Range (ATR)
- VTGN 0.25
- ONCY 0.07
- MACD
- VTGN 0.05
- ONCY -0.00
- Stochastic Oscillator
- VTGN 80.74
- ONCY 58.06
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.